	Claim #10 Date Filed: 5/20/2024
Fill in this information to identify the case:	
Debtor 1 CPA Global Limited	
Debtor 2 (Spouse, if filing)	
United States Bankruptcy Court for the: Northern District of Texas	
Case number <u>24-840040-sgj/11</u>	

Official Form 410

Proof of Claim

04/22

Read the instructions before filling out this form. This form is for making a claim for payment in a bankruptcy case. Do not use this form to make a request for payment of an administrative expense. Make such a request according to 11 U.S.C. § 503.

Filers must leave out or redact information that is entitled to privacy on this form or on any attached documents. Attach redacted copies of any documents that support the claim, such as promissory notes, purchase orders, invoices, itemized statements of running accounts, contracts, judgments, mortgages, and security agreements. Do not send original documents; they may be destroyed after scanning. If the documents are not available, explain in an attachment.

A person who files a fraudulent claim could be fined up to \$500,000, imprisoned for up to 5 years, or both. 18 U.S.C. §§ 152, 157, and 3571.

Fill in all the information about the claim as of the date the case was filed. That date is on the notice of bankruptcy (Form 309) that you received.

	Who is the current creditor?	CPA Global Limited Name of the current creditor (the p	erson or entity to be paid for this c	aim)		
		Other names the creditor used with	the debtor		<u> </u>	
2.	Has this claim been acquired from someone else?	☑ No □ Yes. From whom?		· · · · · · · · · · · · · · · · · · ·	,	
3.	Where should notices and payments to the	Where should notices to the	creditor be sent?	Where should payme different)	nts to the credit	or be sent? (if
	creditor be sent?	CPA Global Limited		CPA Global Limite	ed	
	Federal Rule of Bankruptcy Procedure	Name		Name		
	(FRBP) 2002(g)	789 E. Eisenhower Park	way	PO Box 18263 Number Street	··· –	<u> </u>
			MI 48108	Palatine	IL	60055
		City S	VI 48108 State ZIP Code	City	State	ZIP Cod
	RECEIVED	Contact phone 01204067062	2	Contact phone 012040	67062	
		_				
	MAY 2 0 2024	Contact email finance@cpa	global.com	Contact email fi <u>nance</u>	@cpaglobal.c	<u>.om</u>
Z	MAY 2 0 2024 Mancarsonconsultan	Uniform claim identifier for electron	-	use one):		<u>:om_</u>
	MANCARSONCONSULTAN	Uniform claim identifier for electron	nic payments in chapter 13 (if you t	use one):		<u></u>
	MANCARSONCONSULTAN	Uniform claim identifier for electron	nic payments in chapter 13 (if you t	use one): 		
4.	MANCARSONCONSULTAN	Uniform claim identifier for electron	urt claims registry (if known)	use one): 	_	
4.	Does this claim amend one already filed?	Uniform claim identifier for electron S No SNo Yes. Claim number on co No No	urt claims registry (if known)	use one): 	_	
4.	Does this claim amend one already filed? Do you know if anyone else has filed a proof of claim for this claim?	Uniform claim identifier for electron S No SNo Yes. Claim number on co No No	nic payments in chapter 13 (if you r	use one): 	Filed on MM	

6.	Do you have any number you use to identify the debtor?	No \mathbf{V} Yes. Last 4 digits of the debtor's account or any number you use to identify the debtor: $\underline{3}$ $\underline{8}$ $\underline{5}$ $\underline{6}$		
7.	How much is the claim?	 \$31,023.78. Does this amount include interest or other charges? ☑ No ☑ Yes. Attach statement itemizing interest, fees, expenses, or other charges required by Bankruptcy Rule 3001(c)(2)(A). 		
8.	What is the basis of the claim?	Examples: Goods sold, money loaned, lease, services performed, personal injury or wrongful death, or credit card. Attach redacted copies of any documents supporting the claim required by Bankruptcy Rule 3001(c). Limit disclosing information that is entitled to privacy, such as health care information. Patent Renewal Services		
9.	Is all or part of the claim secured?	 No Yes. The claim is secured by a lien on property. Nature of property: Real estate. If the claim is secured by the debtor's principal residence, file a <i>Mortgage Proof of Claim</i> <i>Attachment</i> (Official Form 410-A) with this <i>Proof of Claim</i>. Motor vehicle Other. Describe: Basis for perfection: Attach redacted copies of documents, if any, that show evidence of perfection of a'security interest (for example, a mortgage, lien, certificate of title, financing statement, or other document that shows the lien has been filed or recorded.)		
		Value of property: \$ Amount of the claim that is secured: \$ Amount of the claim that is unsecured: \$(The sum of the secured and unsecured amounts should match the amount in line 7		
KU	RECEIVED may 2 0 2024 irtzmancarsonconsult	Amount necessary to cure any default as of the date of the petition: \$ Annual Interest Rate (when case was filed)% Grad Fixed Variable		
10.	Is this claim based on a lease?	 ✓ No □ Yes. Amount necessary to cure any default as of the date of the petition. 		
11. Is this claim subject to a ☑ No right of setoff?				
0	ficial Form 410	Proof of Claim page 2		

2. Is all or part of the claim	Mo No				
entitled to priority under 11 U.S.C. § 507(a)?	🛛 Yes. Check	cone:	Amount entitled to p	orior	
A claim may be partly priority and partly		tic support obligations (including alimony and child si C. § 507(a)(1)(A) or (a)(1)(B).	upport) under \$		
nonpriority. For example, in some categories, the law limits the amount entitled to priority.	Up to \$ persona	3,350* of deposits toward purchase, lease, or rental al, family, or household use. 11 U.S.C. § 507(a)(7).	of property or services for \$		
	bankru	salaries, or commissions (up to \$15,150*) earned wotcy petition is filed or the debtor's business ends, wh C. § 507(a)(4).	ithin 180 days before the nichever is earlier. \$		
	_	or penalties owed to governmental units. 11 U.S.C. §	507(a)(8). \$		
	_	utions to an employee benefit plan. 11 U.S.C. § 507(
		Specify subsection of 11 U.S.C. § 507(a)() that ap			
4 to be even	* Amounts	are subject to adjustment on 4/01/25 and every 3 years after	that for cases begun on or after the date of adjustment.		
Part 3: Sign Below		- · · <u>- · · · · · · · · · · · · · · · ·</u>			
The person completing	Check the appro	ppriate box:			
this proof of claim must sign and date it.	I am the cre	editor.			
FRBP 9011(b).	I am the cre	editor's attorney or authorized agent.			
If you file this claim	🗐 I am the tru	stee, or the debtor, or their authorized agent. Bankn	uptcy Rule 3004.		
electronically, FRBP 5005(a)(2) authorizes courts	🔲 lam a guai	antor, surety, endorser, or other codebtor. Bankrupt	cy Rule 3005.		
to establish local rules					
specifying what a signature is.	I understand that	t an authorized signature on this Proof of Claim serv	es as an acknowledgment that when calculating	the	
	amount of the cl	aim, the creditor gave the debtor credit for any paym	ents received toward the debt.		
A person who files a fraudulent claim could be fined up to \$500,000, imprisoned for up to 5	I have examined the information in this <i>Proof of Claim</i> and have a reasonable belief that the information is true and correct.				
years, or both.					
18 U.S.C. §§ 152, 157, and 3571.	04/26/2024				
	Executed on da				
		<i>س</i> ر			
		•			
	8Signature				
	B 1 <i>((</i>)	of the second size is a second size in a finite second sec	- eleim		
	Print the name	of the person who is completing and signing this Mansi Wadhwa			
	Name				
		Firet name Middle name	Last name		
	Title	Lead Collections Specialist			
	Company	CPA Global Limited			
RECEIVED	Company	Identify the corporate servicer as the company if the aut	norized agent is a servicer.		
		789 E. Eisenhower Parkway			
	Address	Number Street			
may 2 0 2024		Ann Arbor	MI 48108		
MAY 2 0 2024					
MAY 2 0 2024 Zmancarsonconsultant	ý	City	State ZIP Code		

Official Form 410

Proof of Claim

Part of Clarivate



Invoice U483121

Eiger Biopharmaceuticals Inc Attn: Matthew Bys 2155 Park Boulevard 350 Cambridge Avenue Suite 350 Palo Alto CA 94306 USA

This Invoice has been issued either in line with your contract terms, or in response to renewal instructions, for the following 53 Patent cases.

The costs on this Invoice may differ from the estimated costs in the Renewal Notice due to fluctuations in exchange rates, official charge increases and any applicable late charges.

You should note that interest will be charged on any amounts overdue at the rate of 1% per month or part thereof.

Total amount due

US\$ 48,251.16

You must allow time for your payment to clear by 29 March 2024.

Purchase Order Number: 3010

How to pay this Invoice

Please pay using one of the methods below and provide details of any credit being used.

Bank transfer

40-05-15
69417697
CPA Global Limited
MIDLGB22XXX
GB24MIDL40051569417697

The transaction reference should include your CPA Global account and invoice number.

Cheque

Cheques must be made payable to CPA Global Limited. Please reference your CPA Global Account number or Invoice number on the cheque. For convenience, please send cheques to our North American affiliate at the following address for onward provision to CPA Global Limited. CPA Global Limited

PO Box 18263 Palatine, IL 60055- 8263 USA

Cheques may also be sent directly to CPA Global Limited to the address shown at the foot of this invoice.

ACH Payment

HSBC Bank USA Na 425 5th Avenue, New York, NY 10018 Account Name: CPA Global Limited Routing Number: 022000020 021001088 ABA Number: MRMDUS33 SWIFT Code:

Account Number: 783009631

28 February 2024

Eiger Biopharmaceuticals, Inc. CPA Global account number: 2493856 Account currency: US Dollar

.........

We are here to help

North America Customer Engagement Email: finance@cpaglobal.com

Phone: 1-866-739-2239

Operated by CPA Global 789 E. Eisenhower Parkway Ann Arbor MI 48108 USA

Note: Please do not make cheques payable to CPA Global North America LLC.


Please let us know if you would like to:

- learn about RENEW, our online patents and designs portfolio management tool
- receive the information in this document as a data file in the future
- have your cases listed in a different order in the future
- change your contact details

Service location

Please note that CPA Global Limited's renewals service is performed outside of the US. Form W8-BEN is available upon request.

a la



red as a company under the Companies (Jersey) Law 1991, number 93743 red Office Liberation House, Castle Street, St Heller, Jersey, JE1 18L Chanr bal Limited previously registered as Computer Patent Annulties Limited et Islands

Page 1 of 11

Part of Clarivate

Date 28 February 2024 2493856

CPA Global account number Client name Eiger Biopharmaceuticals, Inc.

Invoice U483121 continued

Total amount due US\$ 48,251.16

Charges

Official Charge

This represents the amount we pay to relevant registries in each jurisdiction and which may vary from time to time.

Country Charge* This charge relates to the infrastructure, CPA Global personnel and third parties (as appropriate) required in order to execute a

I his charge relates to the infrastructure, CPA Global personnel and third parties (as appropriate) required in order to execute a renewal in a particular jurisdiction. CPA Global maintains a schedule of applicable Country Charges (which may be updated from time to time), a current copy of which is available on request. Administration Charge (also referred to as Service Charge) This charge relates to the systems and CPA Global personnel that determine which patents need to be renewed in which jurisdictions at which point in time. * The Official Charge and Country Charge as well as any other sums of money that may at any time require to be converted from one currency into the currency in which we invoice you will be converted at our rates and are subject to a charge for funds management e.g. managing clobal transactions, currency circle argoing requires required to a subject to a charge for funds management e.g. managing global transactions, currency risk exposure, credit risk and financing renewal payments.

For more information please refer to your written contract (if applicable), or the terms and conditions on your Renewal Notice or contact us.

Austria Patent number 3285768 Renewal date 21 Apr 2024 Annuity 09

Involce item number 0001					Cost US\$ 1,022.70
Reference PHARMACEUTICA	L COMPOSITIONS COMPRIS	Klipatrick Townsend & Stock 923405	ton LLP case code	File number 097854-1210092	
Official Charge US\$ 620.37	Country Charge US\$ 202.33	Administration Charge US\$ 200.00			

Belgium Patent number 3285768 Renewal date 21 Apr 2024 Annuity 09

Invoice ltem number 0002	<i>туре</i> Patent	Application number 16783855.6			Cost US\$ 692.92
Reference PHARMACEUTICA	L COMPOSITIONS COMPRIS	Kilpatrick Townsond & Stoc 923406	kton LLP case code	File number 097854-1210093	
Officiel Charge US\$ 245.46	Country Charge US\$ 247.46	Administration Charge			

Bulgaria Patent number 3285768 Renewal date 21 Apr 2024 Annuity 09

Involce Item number 0003	<i>Туре</i> Patent	Application number 16783855.6	Proprietor EIGER BIOPHAF	RMACEUTICALS, INC.	Cost US\$ 820.99
Reference PHARMACEUTICAL	COMPOSITIONS COMPRIS	Klipatrick Townsend & Stock 923407	ton LLP case code	File number 097854-1210094	
Official Charge US\$ 299.64	Country Charge US\$ 321.35	Administration Charge			

Czechia Patent number 3285768 Renewal date 21 Apr 2024 Annuity 09

Invoice Item number 0004	<i>Type</i> Patent	Application number 16783855.6	Proprietor EIGER BIOPHAR	RMACEUTICALS, INC.	Cost US\$ 602.77
Reference PHARMACEUTICAL	COMPOSITIONS COMPRIS	Klipstrick Townsend & Stock 923408	Non LLP case code	File number 097854-1210095	
Official Charge US\$ 176.59	Country Charge US\$ 226.18	Administration Charge US\$ 200,00	na fan ne en anten gener in strat in strat in strat in de anten in er gener		

Page 2 of 11

÷

t ,

Part of Clarivate

Date	CPA Global account number	Client name
28 February 2024	2493856	Eiger Biopharmaceuticals, Inc.

Invoice U483121 continued

Invoice item number 0005	<i>туре</i> Patent	Application number 16783855,6	Proprietor EIGER BIOPHARN	ACEUTICALS, INC.	Cos US\$ 920.53
Reference PHARMACEUTICAL	COMPOSITIONS COMPRIS	Kilpatrick Townsend & Stockton 923409	LLP case code	File number 097854-1210097	
Official Charge US\$ 442.04	Country Charge US\$ 278.49	Administration Charge US\$ 200.00			
France Patent nu	mber 3285768 Renewal o	date 21 Apr 2024 Ann	uity 09		
Invoice item number 0006	<i>Туре</i> Patent	Application number 16783855.6	Proprietor EIGER BIOPHARN	ACEUTICALS, INC.	ده US\$ 696.1
		Kilpatrick Townsend & Stockton	LLP case code	File number	
Official Charge	COMPOSITIONS COMPRIS	923416 Administration Charge		097854-1210099	
US\$ 267.79	US\$ 228.36	US\$ 200.00			
Hungary Patent r	number 3285768 Renewa	Il date 21 Apr 2024 Ai	nuity 09		
Involce item number 0007	Type Patent	Application number 16783855.6	Proprietor EIGER BIOPHAR	ACEUTICALS, INC.	Cos US\$ 999.27
Reference PHARMACEUTICAL	COMPOSITIONS COMPRIS	Kilpatrick Townsend & Stockton 923417	LLP case coda	File number 097854-1210101	
PHARMACEUTICAL Official Charge US\$ 570.69	Country Charge US\$ 228.58	923417 Administration Charge US\$ 200.00	LLP case code		
PHARMACEUTICAL Official Charge US\$ 570.69	Country Charge US\$ 228.58	923417 Administration Charge US\$ 200.00	nnuity 09 Proprietor		
PHARMACEUTICAL Official Charge US\$ 570,69 Romania Patent Involce item number 0008 Reference	Country Charge US\$ 228.58 number 3285768 Renewa 7909	923417 Administration Charge US\$ 200.00 al date 21 Apr 2024 A Application number	nnulty 09 Proprietor EIGER BIOPHARI	097854-1210101	cor US\$ 941.6;
PHARMACEUTICAL Official Charge US\$ 570,69 Romania Patent Involce item number 0008 Reference	Country Charge US\$ 228.58 number 3285768 Renewa 7909 Patent	923417 Administration Charge US\$ 200.00 al date 21 Apr 2024 A Application number 16783855.6 Kilpatrick Townsend & Stockton	nnulty 09 Proprietor EIGER BIOPHARI	097854-1210101 MACEUTICALS, INC. File number	
PHARMACEUTICAL Official Charge US\$ 570.69 Romania Patent Involce item number 0008 Reference PHARMACEUTICAL Official Charge US\$ 386.80	Country charge US\$ 228.58 number 3285768 Renews 7ype Patent COMPOSITIONS COMPRIS Country Charge US\$ 354.82	923417 Administration Charge U\$\$ 200.00 al date 21 Apr 2024 A Application number 16783855.6 Kilpatrick Townsend & Stackton 923419 Administration Charge U\$\$ 200.00	nnuity 09 Proprietor EIGER BIOPHARI LLP cese code	097854-1210101 MACEUTICALS, INC. File number	
PHARMACEUTICAL Official Charge US\$ 570.69 Romania Patent Involce item number 0008 Reference PHARMACEUTICAL Official Charge US\$ 386.80	Country charge US\$ 228.58 number 3285768 Renews 7ype Patent COMPOSITIONS COMPRIS Country Charge US\$ 354.82	923417 Administration Charge U\$\$ 200.00 al date 21 Apr 2024 A Application number 16783855.6 Kilpatrick Townsend & Stackton 923419 Administration Charge	nnuity 09 Froprietor EIGER BIOPHARI LLP cese code Annuity 09 Froprietor	097854-1210101 MACEUTICALS, INC. File number 097854-1210103	US\$ 941.6
PHARMACEUTICAL Official Charge US\$ 570.69 Romania Patent Involce item number 0008 Reference PHARMACEUTICAL Official Charge US\$ 386.80 Switzerland Pate Involce item number 0009 Reference	Country Charge US\$ 228.58 number 3285768 Renewa Type Patent COMPOSITIONS COMPRIS Country Charge US\$ 354.82 ent number 3285768 Rene Type	923417 Administration Charge U\$\$ 200.00 al date 21 Apr 2024 A Application number 16783855.6 Kilpatrick Townsend & Stackton 923419 Administration Charge U\$\$ 200.00 ewal date 21 Apr 2024 Application number	nnuity 09 Proprietor EIGER BIOPHARI LLP cess code Annuity 09 Proprietor EIGER BIOPHARI	097854-1210101 MACEUTICALS, INC. File number	US\$ 941.6;
PHARMACEUTICAL Official Charge US\$ 570.69 Romania Patent Involce item number 0008 Reference PHARMACEUTICAL Official Charge US\$ 386.80 Switzerland Pate Involce item number 0009 Reference	Country Charge US\$ 228.58 number 3285768 Renewa 7ype Patent COMPOSITIONS COMPRIS Country Charge US\$ 354.82 ent number 3285768 Rene 7ype Patent	923417 Administration Charge U\$\$ 200.00 al date 21 Apr 2024 A Application number 16783855.6 Kilpstrick Townsend & Stackton 923419 Administration Charge U\$\$ 200.00 ewal date 21 Apr 2024 Application number 16783855.6 Kilpstrick Townsend & Stockton	nnuity 09 Proprietor EIGER BIOPHARI LLP cess code Annuity 09 Proprietor EIGER BIOPHARI	097854-1210101 MACEUTICALS, INC. File number 097854-1210103 MACEUTICALS, INC. File number	
PHARMACEUTICAL Official Charge US\$ 570.69 Romania Patent Involce item number 0008 Reference PHARMACEUTICAL Official Charge US\$ 386.80 Switzerland Pate Invoice Item number 0009 Reference PHARMACEUTICAL Official Charge US\$ 344.94	Country Charge US\$ 228.58 number 3285768 Renewa 7ype Patent COMPOSITIONS COMPRIS Country Charge US\$ 354.82 ent number 3285768 Rene 7ype Patent COMPOSITIONS COMPRIS Country Charge US\$ 404.91	923417 Administration Charge U\$\$ 200.00 al date 21 Apr 2024 A Application number 16783855.6 Kilpatrick Townsend & Stackton 923419 Administration Charge U\$\$ 200.00 ewai date 21 Apr 2024 Application number 16783855.6 Kilpatrick Townsend & Stackton 923421 Administration Charge	nnuity 09 Proprietor EIGER BIOPHARI LLP cess code Annuity 09 Proprietor EIGER BIOPHARI	097854-1210101 MACEUTICALS, INC. File number 097854-1210103 MACEUTICALS, INC. File number	US\$ 941.6
PHARMACEUTICAL Official Charge US\$ 570.69 Romania Patent Involce item number 0008 Reference PHARMACEUTICAL Official Charge US\$ 386.80 Switzerland Pate Invoice Item number 0009 Reference PHARMACEUTICAL Official Charge US\$ 344.94	Country Charge US\$ 228.58 number 3285768 Renewa 7ype Patent COMPOSITIONS COMPRIS Country Charge US\$ 354.82 ent number 3285768 Rene 7ype Patent COMPOSITIONS COMPRIS Country Charge US\$ 404.91	923417 Administration Charge U\$\$ 200.00 al date 21 Apr 2024 A Application number 16783855.6 Kilpatrick Townsend & Stackton 923419 Administration Charge U\$\$ 200.00 ewal date 21 Apr 2024 Application number 16783855.6 Kilpatrick Townsend & Stackton 923421 Administration Charge U\$\$ 200.00	nnuity 09 Proprietor EIGER BIOPHARI LLP case code Annuity 09 Proprietor EIGER BIOPHARI LLP case code Annuity 09 Proprietor	097854-1210101 MACEUTICALS, INC. File number 097854-1210103 MACEUTICALS, INC. File number	US\$ 941.6 co US\$ 949.8 Co
PHARMACEUTICAL Official Charge US\$ 570.69 Romania Patent Involce Item number 0008 Reference PHARMACEUTICAL Official Charge US\$ 386.80 Switzerland Pate Involce Item number 0009 Reference PHARMACEUTICAL Official Charge US\$ 344.94 Great Britain Pat Involce Item number 0010 Reference	Country Charge US\$ 228.58 number 3285768 Renewa Type Patent COMPOSITIONS COMPRIS Country Charge US\$ 354.82 ent number 3285768 Rene Type Patent COMPOSITIONS COMPRIS Country Charge US\$ 404.91 tent number 3285768 Ren Type	923417 Administration Charge U\$\$ 200.00 al date 21 Apr 2024 A Application number 16783855.6 Kilpatrick Townsend & Stackton 923419 Administration Charge U\$\$ 200.00 ewal date 21 Apr 2024 Application number 16783855.6 Kilpatrick Townsend & Stockton 923421 Administration Charge U\$\$ 200.00 ewal date 21 Apr 2024 Application number	nnuity 09 Proprietor EIGER BIOPHARI LLP case code Annuity 09 Proprietor EIGER BIOPHARI LLP case code Annuity 09 Proprietor EIGER BIOPHARI	097854-1210101 MACEUTICALS, INC. File number 097854-1210103 MACEUTICALS, INC. File number 097854-1210105	US\$ 941.6



rs 545772 ISO 8051:203 CPA Global Limited Registered office Liberation House, Castle Street, St Heller, Jensey, JET 18L Channel Islands CPA Global Limited previously registered as Computer Patent Annuities Limited

.

Part of Clarivate

Date	CPA Global account number	Client neme
28 February 2024	2493856	Eiger Biopharmaceuticals, Inc.

Invoice U483121 continued

involce item number 0011	<i>туре</i> Patent	Application number 16783855.6	Proprietor EIGER BIOPHARI	MACEUTICALS, INC.	cos US\$ 718.87
Reference PHARMACEUTICAL	COMPOSITIONS COMPRIS	Kilpetrick Townsend & Stockton L 923411	LP case code	File number 097854-1210098	
Dificial Charge US\$ 254.79	Country Charge US\$ 264.08	Administration Charge US\$ 200.00			
			Annuity 09		
Involce liem number D012	Type Patent	Application number 16783855.6	Proprietor EIGER BIOPHARI	MACEUTICALS, INC.	دمع US\$ 790.09
Reference PHARMACEUTICAL	COMPOSITIONS COMPRIS	Klipetrick Townsend & Stockton I 923420	LP case code	File number 097854-1210104	
Official Charge US\$ 386.42	Country Charge US\$ 203.67	Administration Charge US\$ 200.00			
Türkiye Patent nı	umber 2021/00732 Renew	/al date 21 Apr 2024	Annuity 09		
invoice item number 0013	<i>Туре</i> Patent	Application number 16783855.6	Propriator EIGER BIOPHARI	MACEUTICALS, INC.	<i>cos</i> US\$ 409.82
Reference		Klipatrick Townsend & Stockton I	LP case code	File number	
	COMPOSITIONS COMPRIS	923422		097854-1210106	
PHARMACEUTICAL	COMPOSITIONS COMPRIS Country Charge US\$ 37.13			097854-1210106	
PHARMACEUTICAL Official Charge US\$ 172.69	Country Charge US\$ 37.13	923422 Administration Charge	Annuity 09	097854-1210106	
PHARMACEUTICAL Official Charge US\$ 172.69	Country Charge US\$ 37.13	923422 Administration Charge US\$ 200.00	Annuity 09 Proprietor	097854-1210106	
PHARMACEUTICAL official Charge US\$ 172.69 China Patent num Invoice liem number 0014 Reference	Country Charge US\$ 37.13 nber 201680023413.9 Rei Type	923422 Administration Charge US\$ 200.00 newal date 21 Apr 2024 Application number	Annuity 09 Propristor EIGER BIOPHAR		
PHARMACEUTICAL official Charge US\$ 172.69 China Patent num Invoice liem number 0014 Reference	Country Charge US\$ 37.13 nber 201680023413.9 Rei Type Patent	923422 Administration Charge US\$ 200,00 newal date 21 Apr 2024 Application number 201680023413.9 Kilpetrick Townsend & Stockton I	Annuity 09 Propristor EIGER BIOPHAR	MACEUTICALS, INC.	
PHARMACEUTICAL orticial Charge US\$ 172.69 China Patent num Invoice Item number D014 Reference PHARMACEUTICAL Difficial Charge US\$ 383.82	Country Charge US\$ 37.13 nber 201680023413.9 Ref Type Patent COMPOSITIONS COMPRIS Country Charge US\$ 269.57	923422 Administration Charge US\$ 200,00 newal date 21 Apr 2024 Application number 201680023413.9 Klipatrick Townsend & Stockton I 776861 Administration Charge	Annuity 09 Propristor EIGER BIOPHARI	MACEUTICALS, INC.	
PHARMACEUTICAL orticial Charge US\$ 172.69 China Patent num Invoice liem number D014 Reference PHARMACEUTICAL Official Charge US\$ 383.82	Country Charge US\$ 37.13 nber 201680023413.9 Ref Type Patent COMPOSITIONS COMPRIS Country Charge US\$ 269.57	923422 Administration Charge US\$ 200,00 newal date 21 Apr 2024 Application number 201680023413.9 Kilpatrick Townsend & Stockton I 776861 Administration Charge US\$ 200,00	Annuity 09 Proprietor EIGER BIOPHARI LLP case code 024 Annuity 09 Proprietor	MACEUTICALS, INC.	
PHARMACEUTICAL official Charge US\$ 172.69 China Patent num Involce ilem number D014 Reference PHARMACEUTICAL official Charge US\$ 383.82 Germany Patent Involce ilem number D015 Reference	Country Charge US\$ 37.13 nber 201680023413.9 Rei Type Patent COMPOSITIONS COMPRIS Country Charge US\$ 269.57 number 602016050656.4 Type	923422 Administration Charge US\$ 200,00 newal date 21 Apr 2024 Application number 201680023413.9 Kilpatrick Townsend & Stockton I 776861 Administration Charge US\$ 200,00 Renewal date 21 Apr 20 Application number	Annuity 09 Proprietor EIGER BIOPHARI LLP case code 024 Annuity 09 Proprietor EIGER BIOPHAR	MACEUTICALS, INC. File number 097854-1064652	US\$ 853.39
PHARMACEUTICAL official Charge US\$ 172.69 China Patent num Involce ilem number D014 Reference PHARMACEUTICAL official Charge US\$ 383.82 Germany Patent Involce ilem number D015 Reference	Country Charge US\$ 37.13 nber 201680023413.9 Ref Type Patent COMPOSITIONS COMPRIS Country Charge US\$ 269.57	923422 Administration Charge US\$ 200,00 newal date 21 Apr 2024 Appleation number 201680023413.9 Klipatrick Townsend & Stockton I 776861 Administration Charge US\$ 200,00 Renewal date 21 Apr 20 Appleation number 16783855.6 Klipatrick Townsend & Stockton I	Annuity 09 Proprietor EIGER BIOPHARI LLP case code 024 Annuity 09 Proprietor EIGER BIOPHAR	MACEUTICALS, INC. File number 097854-1064652 MACEUTICALS, INC. File number	US\$ 853.39
PHARMACEUTICAL official Charge US\$ 172.69 China Patent num Invoice liem number 0014 Reference PHARMACEUTICAL Official Charge US\$ 383.82 Germany Patent Invoice liem number 0015 Reference PHARMACEUTICAL Official Charge US\$ 520.70 Italy Patent number	Country Charge US\$ 37.13 nber 201680023413.9 Ref Type Patent COMPOSITIONS COMPRIS Country Charge US\$ 269.57 number 602016050656.4 Type Patent COMPOSITIONS COMPRIS Country Charge US\$ 286.01	923422 Administration Charge US\$ 200,00 newal date 21 Apr 2024 Application number 201680023413.9 Kilpatrick Townsend & Stockton I 776861 Administration Charge US\$ 200,00 Renewal date 21 Apr 20 Application number 16783855.6 Kilpatrick Townsend & Stockton I 923410 Administration Charge US\$ 200,00	Annuity 09 Proprietor EIGER BIOPHARI LLP case code 024 Annuity 09 Proprietor EIGER BIOPHARI LLP case code Annuity 09	MACEUTICALS, INC. File number 097854-1064652 MACEUTICALS, INC. File number	US\$ 853.39 <i>c</i> es US\$ 1,006.71
PHARMACEUTICAL Official Charge US\$ 172.69 China Patent num Invoice item number 0014 Reference PHARMACEUTICAL Official Charge US\$ 3B3.82 Germany Patent Invoice item number 0015 Reference PHARMACEUTICAL Official Charge US\$ 520.70	Country Charge US\$ 37.13 nber 201680023413.9 Ref Type Patent COMPOSITIONS COMPRIS Country Charge US\$ 269.57 number 602016050656.4 Type Patent COMPOSITIONS COMPRIS Country Charge US\$ 286.01	923422 Administration Charge US\$ 200,00 newal date 21 Apr 2024 Appleation number 201680023413.9 Kilpatrick Townsend & Stockton I 776861 Administration Charge US\$ 200,00 Renewal date 21 Apr 20 Application number 16783855.6 Kilpatrick Townsend & Stockton I 923410 Administration Charge US\$ 200,00	Annuity 09 Proprietor EIGER BIOPHAR LP case code 024 Annuity 09 Proprietor EIGER BIOPHAR LIP case code Annuity 09 Proprietor	MACEUTICALS, INC. File number 097854-1064652 MACEUTICALS, INC. File number	US\$ 853.39
PHARMACEUTICAL ordicial Charge US\$ 172.69 China Patent num Invoice item number D014 Reference PHARMACEUTICAL Official Charge US\$ 383.82 Germany Patent Invoice item number D015 Reference PHARMACEUTICAL official Charge US\$ 520.70 Italy Patent number D016 Reference	Country Charge US\$ 37.13 nber 201680023413.9 Ref Type Patent COMPOSITIONS COMPRIS Country Charge US\$ 269.57 number 602016050656.4 Type Patent COMPOSITIONS COMPRIS Country Charge US\$ 286.01	923422 Administration Charge US\$ 200,00 newal date 21 Apr 2024 Appleation number 201680023413.9 Kilpatrick Townsend & Stockton II 776861 Administration Charge US\$ 200,00 Renewal date 21 Apr 20 Application number 16783855.6 Kilpatrick Townsend & Stockton II 923410 Administration Charge US\$ 200,00 newal date 21 Apr 2024 Application number	Annuity 09 Proprietor EIGER BIOPHARI LP case code 024 Annuity 09 Proprietor EIGER BIOPHARI Annuity 09 Proprietor EIGER BIOPHARI	MACEUTICALS, INC. File number 097854-1064852 MACEUTICALS, INC. File number 097854-1210096	US\$ 853.39 cos US\$ 1,006.71 Cos
PHARMACEUTICAL ordicial Charge US\$ 172.69 China Patent num Invoice item number D014 Reference PHARMACEUTICAL Official Charge US\$ 383.82 Germany Patent Invoice item number D015 Reference PHARMACEUTICAL official Charge US\$ 520.70 Italy Patent number D016 Reference	Country Charge US\$ 37.13 nber 201680023413.9 Ref Type Patent COMPOSITIONS COMPRIS Country Charge US\$ 269.57 - number 602016050656.4 Type Patent COMPOSITIONS COMPRIS Country Charge US\$ 286.01 her 502021000005546 Ref Type Patent	923422 Administration Charge US\$ 200,00 newal date 21 Apr 2024 Application number 201680023413.9 Klipatrick Townsend & Stockton I 776861 Administration Charge US\$ 200,00 Renewal date 21 Apr 20 Application number 16783855.6 Klipatrick Townsend & Stockton I US\$ 200,00 newal date 21 Apr 2024 Application number 16783855.6 Klipatrick Townsend & Stockton I	Annuity 09 Proprietor EIGER BIOPHARI LP case code 024 Annuity 09 Proprietor EIGER BIOPHARI Annuity 09 Proprietor EIGER BIOPHARI	MACEUTICALS, INC. File number 097854-1064652 MACEUTICALS, INC. File number 097854-1210096 MACEUTICALS, INC. File number	US\$ 853.39 cos US\$ 1,006.71 Cos

/

Page 4 of 11

, 1

1

٢

r v

Part of Clarivate

Date	CPA Global account number	Client name
28 February 2024	2493856	Eiger Biopharmaceuticals, Inc.

Invoice U483121 continued

Greece Patent n	umber 3100081	Renewal date 01 May 2024	Annuity 10		
Involce item number 0017	_{Туре} Patent	Application number 15785846.5	Proprietor EIGER BIOPHAF	RMACEUTICALS, INC.	Cost US\$ 762.35
Reference TREATMENT OF HE	EPATITIS DELTA VI	Kilpatrick Townsend & St RUS 860596	ockton LLP case code	File number 097854-1140306	
Official Charge US\$ 282.67	Country Charge US\$ 279.68	Administration Charge US\$ 200.00	nen genergin in genergen in de lei skarge en genergin de verden for a		
Austria Patent n	umber 3137078	Renewal date 01 May 2024	Annuity 10	1. 10.0140 - 1044 - 1. 1044 - 1. 1044 - 1. 1044 - 1. 1045 - 1. 1045 - 1. 1045 - 1. 1045 - 1. 1045 - 1. 1045 - 1.	
Invoice Item number	umber 3137078 ^{7ype} Patent	Renewal date 01 May 2024 Application number 15785846.5	Proprietor	RMACEUTICALS, INC.	
Austria Patent n Invoice Item number 0018 Reference TREATMENT OF HE	Type Patent	Application number 15785846.5 Kilpetrick Townsend & St	Proprietor EIGER BIOPHAF	RMACEUTICALS, INC. File number 097854-1140293	<i>Cost</i> US\$ 1,271.90

Belgium Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	voice item number Type		Proprietor		Cost
0019	Patent	15785846.5 EIGER BIOPHARMACEUTICALS, INC.		RMACEUTICALS, INC.	US\$ 722.69
Reference		Kilpatrick Townsend & Stockto	n LLP case code	File number	
TREATMENT OF HE	EPATITIS DELTA VIRUS	860587		097854-1140294	
Official Charge	Country Charge	Administration Charge			
US\$ 275.23	US\$ 247.46	US\$ 200.00			

Bulgaria Patent number 3137078 Renewal date 01 May 2024 Annuity 10

involce item number	Туре	Application number	Proprietor		Cost
0020	Patent	15785846.5	15785846.5 EIGER BIOPHARMACEUTICALS, INC.		US\$ 915.59
Reference		Kilpatrick Townsend & Stock	don LLP case code	File number	
TREATMENT OF HE	EPATITIS DELTA VIRUS	860588		097854-1140295	
Official Charge	Country Charge	Administration Charge			
US\$ 394.24	US\$ 321.35	US\$ 200.00			

Cyprus Patent number 3137078 Renewal date 01 May 2024 Annuity 10

invoice item number 0021	յչթե Patent	Application number 15785846.5	Proprietor EIGER BIOPHAR	RMACEUTICALS, INC.	Cost US\$ 805.49
Reference TREATMENT OF H	EPATITIS DELTA VIRUS	Kilpatrick Townsend & Stoc 860589	kton LLP case code	-File number 097854-1140297	
Official Charge US\$ 267,79	Country Charge	Administration Charge			

Czechia Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number 0022	<i>Туре</i> Patent	Application number 15785846.5	Proprietor EIGER BIOPHAR	RMACEUTICALS, INC.	Cost US\$ 661.64
Reference TREATMENT OF H	EPATITIS DELTA VIRUS	Kilpetrick Townsend & Stockton 860590	LLP case code	File number 097854-1140298	
Official Charge US\$ 235,46	Country Charge US\$ 226.18	Administration Charge US\$ 200.00			



CPA Global Limited Registered as a company under the Companies (Jersey) Law 1991, number 93743 Registered Office Liberation House, Castle Street, St Heller, Jersey, JE1 18L Channel Islands CPA Global Limited previously registered as Computer Patent Annullies Limited

Page 5 of 11

CPA GLOBAL Part of Clarivate

Date	CPA Global account number	Client name
28 February 2024	2493856	Eiger Biopharmaceuticals, Inc.

Invoice U483121 continued

voice item number 023	^{7ype} Patent	Application number 15785846.5	Proprietor EIGER BIOPHARMACE	UTICALS, INC.	ca US\$ 974.4
eference REATMENT OF HEI	PATITIS DELTA VIRU	Klipatrick Townsend & Stock	don LLP case code	File number 097854-1140300	
fficial Charge IS\$ 495.91	Country Charge US\$ 278.49	Administration Charge US\$ 200.00			
stonia Patent nu	umber 3137078 R	enewal date 01 May 2024	Annuity 10		
voice item number 024	Type Patent	Application number 15785846.5	Proprietor EIGER BIOPHARMACE	UTICALS, INC.	c، US\$ 829.5
REATMENT OF HE	PATITIS DELTA VIRU	Klipstrick Townsend & Stoc IS 860592	don LLP case code	File number 097854-1140301	
fficial Charge IS\$ 304.97	Country Charge US\$ 324.62	Administration Charge US\$ 200.00			
inland Patent nu	umber 3137078 R	enewal date 01 May 2024	Annuity 10		
volce item number 025	<i>туре</i> Patent	Application number 15785846.5	Proprietor EIGER BIOPHARMACE	UTICALS, INC.	دم US\$ 1,060.6
eference REATMENT OF HEI	PATITIS DELTA VIRL	Klipatrick Townsend & Stoc IS 860593	don LLP case code	File number 097854-1140303	
	PATITIS DELTA VIRU Country Charge US\$ 220.92		Kon LLP case code		
REATMENT OF HEI fficial Charge IS\$ 639.73	Country Charge US\$ 220.92	IS 860593 Administration Charge US\$ 200,00			
REATMENT OF HEI fficial Charge IS\$ 639.73 France Patent nu wolce liem number	Country Charge US\$ 220.92 mber 3137078 Ro Type	IS 860593 Administration Charge US\$ 200.00 enewal date 01 May 2024 Application number	Annuity 10 Proprietor	097854-1140303	
REATMENT OF HEI fileial Charge IS\$ 639.73 France Patent nu voice liem number 026 eference	Country Charge US\$ 220.92 mber 3137078 Ro Type Patent	IS 860593 Administration Charge US\$ 200.00 enewal date 01 May 2024 Application number 15785846.5 Kilpatrick Townsend & Stoc	Annuity 10 Proprietor EIGER BIOPHARMACE	097854-1140303 UTICALS, INC.	
REATMENT OF HEI fileial Charge IS\$ 639.73 France Patent nu voice liem number 026 eference	Country Charge US\$ 220.92 mber 3137078 Ro Type	IS 860593 Administration Charge US\$ 200.00 enewal date 01 May 2024 Application number 15785846.5 Kilpatrick Townsend & Stoc	Annuity 10 Proprietor EIGER BIOPHARMACE	097854-1140303	
REATMENT OF HEI ficial Charge IS\$ 639.73 France Patent nui voice liem number 026 eference REATMENT OF HEI	Country Charge US\$ 220.92 mber 3137078 Ro Type Patent PATITIS DELTA VIRL	IS 860593 Administration Charge US\$ 200,00 enewal date 01 May 2024 Application number 15785846,5 Kilpatrick Townsend & Stoc 860594	Annuity 10 Proprietor EIGER BIOPHARMACE	097854-1140303 UTICALS, INC.	
REATMENT OF HEI ficial Charge IS\$ 639.73 France Patent nui volce liem number 026 eference REATMENT OF HEI ficial Charge IS\$ 327.29 lungary Patent n	Country Charge US\$ 220.92 mber 3137078 Re Type Patent PATITIS DELTA VIRL Country Charge US\$ 228.36	IS 860593 Administration Charge US\$ 200,00 enewal date 01 May 2024 Application number 15785846,5 Klipatrick Townsend & Stoc 860594 Administration Charge US\$ 200,00	Annuity 10 Proprietor EIGER BIOPHARMACE	097854-1140303 UTICALS, INC.	cc US\$ 755.6
REATMENT OF HEI ficial Charge IS\$ 639.73 France Patent nui volce liem number 026 eference REATMENT OF HEI ficial Charge IS\$ 327.29	Country Charge US\$ 220.92 mber 3137078 Re Type Patent PATITIS DELTA VIRL Country Charge US\$ 228.36	IS 860593 Administration Charge US\$ 200,00 enewal date 01 May 2024 Application number 15785846,5 Klipatrick Townsend & Stoc 860594 Administration Charge US\$ 200,00	Annuity 10 Proprietor EIGER BIOPHARMACE Hon LLP case cade	097854-1140303 UTICALS, INC. File number 097854-1140304	US\$ 765.6
REATMENT OF HEI fileial Charge IS\$ 639.73 France Patent nu voice item number 026 eference REATMENT OF HEI fileial Charge IS\$ 327.29 Rungary Patent n voice item number 027 eference	Country Charge US\$ 220.92 mber 3137078 Rd Type Patent PATITIS DELTA VIRL Country Charge US\$ 228.36 number 3137078	IS 860593 Administration Charge US\$ 200.00 enewal date 01 May 2024 Application number 15785846.5 Kilpatrick Townsend & Stoc IS 860594 Administration Charge US\$ 200.00 Renewal date 01 May 2024 Application number 15785846.5 Kilpatrick Townsend & Stoc	Annuity 10 Proprietor EIGER BIOPHARMACE Idon LLP case code Annuity 10 Proprietor EIGER BIOPHARMACE	097854-1140303 UTICALS, INC. File number 097854-1140304	
REATMENT OF HEI fileial Charge IS\$ 639.73 France Patent nu voice item number 026 eference REATMENT OF HEI fileial Charge IS\$ 327.29 Rungary Patent n voice item number 027 eference	Country Charge US\$ 220.92 mber 3137078 Re Type Patent PATITIS DELTA VIRL Country Charge US\$ 228.36 humber 3137078 Type Patent	IS 860593 Administration Charge US\$ 200.00 enewal date 01 May 2024 Application number 15785846.5 Kilpatrick Townsend & Stoc IS 860594 Administration Charge US\$ 200.00 Renewal date 01 May 2024 Application number 15785846.5 Kilpatrick Townsend & Stoc	Annuity 10 Proprietor EIGER BIOPHARMACE Idon LLP case code Annuity 10 Proprietor EIGER BIOPHARMACE	097854-1140303 UTICALS, INC. File number 097854-1140304 UTICALS, INC. File number	US\$ 765.6
REATMENT OF HEI ficial Charge IS\$ 639.73 France Patent nui voice item number 026 eference REATMENT OF HEI ficial Charge 1027 eference REATMENT OF HEI ficial Charge IS\$ 570.69	Country Charge US\$ 220.92 mber 3137078 Rd Type Patent PATITIS DELTA VIRL Country Charge US\$ 228.36 number 3137078 Type Patent PATITIS DELTA VIRL Country Charge US\$ 228.58	IS 860593 Administration Charge US\$ 200.00 enewal date 01 May 2024 Application number 15785846.5 Kilpatrick Townsend & Stoc 8 860594 Administration Charge US\$ 200.00 Renewal date 01 May 2024 Application number 15785846.5 Kilpatrick Townsend & Stoc 860597 Administration Charge US\$ 200.00	Annuity 10 Proprietor EIGER BIOPHARMACE Idon LLP case code Annuity 10 Proprietor EIGER BIOPHARMACE	097854-1140303 UTICALS, INC. File number 097854-1140304 UTICALS, INC. File number	US\$ 765.6
REATMENT OF HEI ficial Charge IS\$ 639.73 France Patent nui voice item number 026 eference REATMENT OF HEI ficial Charge 1027 eference REATMENT OF HEI ficial Charge IS\$ 570.69	Country Charge US\$ 220.92 mber 3137078 Rd Type Patent PATITIS DELTA VIRL Country Charge US\$ 228.36 number 3137078 Type Patent PATITIS DELTA VIRL Country Charge US\$ 228.58	IS 860593 Administration Charge US\$ 200.00 enewal date 01 May 2024 Application number 15785846.5 Kilpatrick Townsend & Stoc 8 860594 Administration Charge US\$ 200.00 Renewal date 01 May 2024 Application number 15785846.5 Kilpatrick Townsend & Stoc 860597 Administration Charge US\$ 200.00	Annuity 10 Proprietor EIGER BIOPHARMACE Annuity 10 Proprietor EIGER BIOPHARMACE iton LLP case cade	097854-1140303	US\$ 755.6 c. US\$ 999.2 C.
REATMENT OF HEI ficial Charge IS\$ 639.73 France Patent nui volce liem number 026 oference REATMENT OF HEI ficial Charge IS\$ 327.29 Aungary Patent n volce liem number 027 oference REATMENT OF HEI ficial Charge IS\$ 570.69 Celand Patent nui volce liem number 028 oference	Country Charge US\$ 220.92 mber 3137078 Re Type Patent PATITIS DELTA VIRL Country Charge US\$ 228.36 humber 3137078 Type Patent PATITIS DELTA VIRL Country Charge US\$ 228.58 number 3137078 R Type	IS 860593 Administration Charge US\$ 200,00 enewal date 01 May 2024 Application number 15785846,5 Klipatrick Townsend & Stoc 860594 Administration Charge US\$ 200,00 Renewal date 01 May 2024 Application number 15785846,5 Klipatrick Townsend & Stoc 860597 Administration Charge US\$ 200,00	Annuity 10 Proprietor EIGER BIOPHARMACE Annuity 10 Proprietor EIGER BIOPHARMACE Annuity 10 Proprietor EIGER BIOPHARMACE	097854-1140303	US\$ 765.6
REATMENT OF HEI ficial Charge IS\$ 639.73 France Patent nui volce liem number 026 oference REATMENT OF HEI ficial Charge IS\$ 327.29 Aungary Patent n volce liem number 027 oference REATMENT OF HEI ficial Charge IS\$ 570.69 Celand Patent nui volce liem number 028 oference	Country Charge US\$ 220.92 mber 3137078 Re Patent PATITIS DELTA VIRL Country Charge US\$ 228.36 humber 3137078 R Type Patent PATITIS DELTA VIRL Country Charge US\$ 228.58 imber 3137078 R Type Patent	IS 860593 Administration Charge US\$ 200,00 enewal date 01 May 2024 Application number 15785846,5 Klipatrick Townsend & Stoc 860594 Administration Charge US\$ 200,00 Renewal date 01 May 2024 Application number 15785846,5 Klipatrick Townsend & Stoc 860597 Administration Charge US\$ 200,00	Annuity 10 Proprietor EIGER BIOPHARMACE Annuity 10 Proprietor EIGER BIOPHARMACE Annuity 10 Proprietor EIGER BIOPHARMACE	097854-1140303	US\$ 755.6

Page 6 of 11

x

Ű

,

۲

r v

Part of Clarivate

Date	CPA Global account number	Client name
28 February 2024	2493856	Eiger Biopharmaceuticals, Inc.

Invoice U483121 continued

Involce item number 0029	_{Туре} Patent		Proprietor EIGER BIOPHARMACEUTICALS, INC.	Cos US\$ 852.34
Reference TREATMENT OF HE	PATITIS DELTA VIRUS	Kilpatrick Townsend & Stockton LLP (860599	case code File number 097854-1140308	
Official Charge US\$ 327.29	Country Charge US\$ 325.05	Administration Charge US\$ 200.00		
Latvia Patent nur	mber 3137078 Renewal	date 01 May 2024 Annuity	10	
Invoice item number D030	^{7ype} Patent		Proprietor EIGER BIOPHARMACEUTICALS, INC.	cos US\$ 1,148.87
Reference TREATMENT OF HE	PATITIS DELTA VIRUS	Kilpatrick Townsend & Stockton LLP (860601	case code File number 097854-1140314	
Official Charge US\$ 476.06	Country Charge US\$ 472.81	Administration Charge US\$ 200.00		
Lithuania Patent	number 3137078 Rene	wal date 01 May 2024 Ann	uity 10	
Invoice item number 0031	<i>туре</i> Patent		Proprietor EIGER BIOPHARMACEUTICALS, INC.	Cos US\$ 978.08
Reference		Kilpatrick Townsend & Stockton LLP	case code File number	
TREATMENT OF HE	PATITIS DELTA VIRUS	860603	097854-1140312	
TREATMENT OF HE Otficial Charge US\$ 343.67	Country Charge US\$ 434.41	860603 Administration Charge US\$ 200.00	097854-1140312	
Official Charge US\$ 343.67	Country Charge US\$ 434.41	Administration Charge US\$ 200.00		
Official Charge US\$ 343.67	Country Charge US\$ 434.41	Administration Charge US\$ 200.00 enewal date 01 May 2024 Application number F	097854-1140312 Annuity 10 Proprietor EIGER BIOPHARMACEUTICALS, INC.	
Official Charge US\$ 343.67 Luxembourg Pai Involce item number 0032 Reference	Country Charge US\$ 434.41 tent number 3137078 Ro Type	Administration Charge US\$ 200.00 enewal date 01 May 2024 Application number F	Annuity 10 ^{Yopristor} 21GER BIOPHARMACEUTICALS, INC.	Cos US\$ 606.14
Official Charge US\$ 343.67 Luxembourg Pai Involce item number 0032 Reference	Country Charge US\$ 434.41 tent number 3137078 Ri Type Patent	Administration Charge US\$ 200.00 enewal date 01 May 2024 Application number F 15785846.5 E Kilpetrick Townsend & Slockton LLP	Annuity 10 Troprietor EIGER BIOPHARMACEUTICALS, INC. cease code File number	
official Charge US\$ 343.67 Involce item number 0032 Reference TREATMENT OF HE Official Charge US\$ 194.89	Country Charge US\$ 434.41 Itent number 3137078 R Type Patent PATITIS DELTA VIRUS Country Charge US\$ 211.25	Administration Charge US\$ 200.00 enewal date 01 May 2024 Application number F 15786866.5 E Klipatrick Townsend & Stockton LLP n 860604 Administration Charge	Annuity 10 Proprietor EIGER BIOPHARMACEUTICALS, INC. Cese code File number 097854-1140313	
official Charge US\$ 343.67 Involce item number 0032 Reference TREATMENT OF HE Official Charge US\$ 194.89	Country Charge US\$ 434.41 Itent number 3137078 R Type Patent PATITIS DELTA VIRUS Country Charge US\$ 211.25	Administration Charge US\$ 200.00 enewal date 01 May 2024 Application number F 15785845.5 E Klipstrick Townsend & Stockton LLP i 850604 Administration Charge US\$ 200.00 al date 01 May 2024 Annui Application number F	Annuity 10 Proprietor EIGER BIOPHARMACEUTICALS, INC. Cese code File number 097854-1140313	US\$ 606.14
official Charge US\$ 343.67 Luxembourg Pat Involce item number 0032 Reference TREATMENT OF HE Official Charge US\$ 194.89 Monaco Patent m Involce item number 0033 Reference	Country Charge US\$ 434.41 tent number 3137078 Ri Patent Patent PATITIS DELTA VIRUS Country Charge US\$ 211.25 number 3137078 Renew Type	Administration Charge US\$ 200.00 enewal date 01 May 2024 Application number F 15785845.5 E Klipstrick Townsend & Stockton LLP i 850604 Administration Charge US\$ 200.00 al date 01 May 2024 Annui Application number F	Annuity 10 Toprietor EIGER BIOPHARMACEUTICALS, INC. Ease code File number 097854-1140313 ty 10 Toprietor EIGER BIOPHARMACEUTICALS, INC.	US\$ 606.14
official Charge US\$ 343.67 Luxembourg Pat Involce item number 0032 Reference TREATMENT OF HE Official Charge US\$ 194.89 Monaco Patent m Involce item number 0033 Reference	Country Charge US\$ 434.41 Itent number 3137078 Ri Type Patent Patent PATITIS DELTA VIRUS Country Charge US\$ 211.25 number 3137078 Renew Type Patent	Administration Charge US\$ 200.00 enewal date 01 May 2024 // Application number F 15785846.5 E Klipatrick Townsend & Stockton LLP / 860604 Administration Charge US\$ 200.00 al date 01 May 2024 Annuu Application number F 15785846.5 E Klipatrick Townsend & Stockton LLP /	Annuity 10 Proprietor EIGER BIOPHARMACEUTICALS, INC. cease code File number 097854-1140313 ty 10 Proprietor EIGER BIOPHARMACEUTICALS, INC. cease code File number	US\$ 606.14
official Charge US\$ 343.67 Involce item number 0032 Reference TREATMENT OF HE Official Charge US\$ 194.89 Monaco Patent n Involce item number 0033 Reference TREATMENT OF HE Official Charge US\$ 275.23	Country Charge US\$ 434.41 tent number 3137078 Ri Patent Patent Patent Patent Country Charge US\$ 211.25 number 3137078 Renew Type Patent Patent Patent Patent Patent	Administration Charge US\$ 200.00 enewal date 01 May 2024 // Application number // 15785846.5 E Klipatrick Townsend & Stockton LLP // 860604 Administration Charge US\$ 200.00 al date 01 May 2024 Annuti Application number // 15785846.5 E Klipatrick Townsend & Stockton LLP // 860605 Administration Charge US\$ 200.00	Annuity 10 Proprietor EIGER BIOPHARMACEUTICALS, INC. cease code File number 097854-1140313 ty 10 Proprietor EIGER BIOPHARMACEUTICALS, INC. cease code File number	US\$ 606.14
official Charge US\$ 343.67 Involce item number 0032 Reference TREATMENT OF HE Official Charge US\$ 194.89 Monaco Patent n Involce item number 0033 Reference TREATMENT OF HE Official Charge US\$ 275.23	Country Charge US\$ 434.41 tent number 3137078 Ri Patent Patent Patent Patent Country Charge US\$ 211.25 number 3137078 Renew Type Patent Patent Patent Patent Patent	Administration Charge US\$ 200.00 enewal date 01 May 2024 // Application number F 15785846.5 E Klipatrick Townsend & Stockton LLP i 860604 Administration Charge US\$ 200.00 al date 01 May 2024 Annul Application number F 15785846.5 E Klipatrick Townsend & Stockton LLP i 860605 Administration Charge US\$ 200.00 enewal date 01 May 2024 A Application number F	Annuity 10 Proprietor EIGER BIOPHARMACEUTICALS, INC. Ease code File number 097854-1140313 hy 10 Proprietor EIGER BIOPHARMACEUTICALS, INC. Ease code File number 097854-1140315	US\$ 606.14 cos US\$ 805.84
official Charge US\$ 343.67 Luxembourg Pai Invoice item number 0032 Reference TREATMENT OF HE Official Charge US\$ 194.89 Monaco Patent m Invoice item number 0033 Reference TREATMENT OF HE Official Charge US\$ 275.23 Netherlands Pate Invoice item number 0034 Reference	Country Charge US\$ 434.41 tent number 3137078 Re Patent Patent Patent Country Charge US\$ 211.25 number 3137078 Renew 7ype Patent	Administration Charge US\$ 200.00 enewal date 01 May 2024 // Application number F 15785846.5 E Klipatrick Townsend & Stockton LLP i 860604 Administration Charge US\$ 200.00 al date 01 May 2024 Annul Application number F 15785846.5 E Klipatrick Townsend & Stockton LLP i 860605 Administration Charge US\$ 200.00 enewal date 01 May 2024 A Application number F	Annuity 10 Topristor EIGER BIOPHARMACEUTICALS, INC. cess code File number 097854-1140313 ty 10 Topristor EIGER BIOPHARMACEUTICALS, INC. cess code File number 097854-1140315 Sannuity 10 Topristor EIGER BIOPHARMACEUTICALS, INC.	

CPA Global Limited Liberation House, Castle Street, St Heller, Jersey JE1 18L Channel Islands www.cpaglobal.com



rs 945772 Iso exertings CPA Global Limited Regletered as a company under the Companies (Jersey) Law 1991, number 93743 Regletered of Cline Liberation House, Castle Street, St Helier, Jensey, JE1 19L Channel Islands CPA Global Limited previously registered as Computer Patent Annulles Limited

Page 7 of 11

~

Dete 28 February 2024	CPA Globel account number 2493856	Client name Eiger Biopharmaceuticals, Inc.		
	33121 continued			
Involce item number	Type	I date 01 May 2024 Annuity 10 Application number Proprietor		Co
0035	Patent	15785846.5 EIGER BIOPHAF	MACEUTICALS, INC.	US\$ 938.4
Reference TREATMENT OF HE	PATITIS DELTA VIRUS	Klipatrick Townsend & Stockton LLP case code 860607	File number 097854-1140317	
Official Charge US\$ 547.02	Country Charge US\$ 191.43	Administration Charge US\$ 200.00	n den en antidat é alleren de la collection d'anne à la dense aller de la dense de la dense de la dense de la d	
Poland Patent nu Involce liem number 0036	umber 3137078 Renewal זעף Patent	date 01 May 2024 Annuity 10 Application number Proprietor 15785846,5 EIGER BIOPHAR	RMACEUTICALS, INC.	ده US\$ 828.50
Reference TREATMENT OF HE	PATITIS DELTA VIRUS	Klipstrick Townsend & Stockton LLP case code 860608	File number 097854-1140318	
Official Charge US\$ 224.51	Country Charge US\$ 403.99	Administration Charge US\$ 200,00		
Portugal Patent	number 3137078 Renew	al date 01 May 2024 Annuity 10		
Involce item number 0037	<i>Туре</i> Patent	Application number Proprietor	RMACEUTICALS, INC.	co US\$ 1,204.6
·····		Kilpatrick Townsend & Stockton LLP case code	File number	

Involce item number	<i>Туре</i>	Application number	Proprietor		Cost
0036	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.		US\$ 828.50
Reference	Reference		Klipatrick Townsend & Stockton LLP case code		
TREATMENT OF H	TREATMENT OF HEPATITIS DELTA VIRUS		860608		
Official Charge US\$ 224.51	Country Charge US\$ 403.99	Administration Charge US\$ 200,00			

Involce item number	<i>Туре</i>	Application number	Proprietor		Cost
0037	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.		US\$ 1,204.61
Reference		Klipatrick Townsend & Stockton LLP case code		File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860609		097854-1140319	
Official Charge US\$ 605.54	Country Charge US\$ 399.07	Administration Charge US\$ 200.00		n na manda a na panana na manangga kawa na kapatang pananina pa manana na manana na manana na manana na mana n	

Romania Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Involce Item number 0038	Type Patent		oprietor IGER BIOPHARMACEUTICALS, INC.	Cost US\$ 1,016.76
Reference TREATMENT OF HE	EPATITIS DELTA VIRUS	Klipatrick Townsend & Stockton LLP ca 860610	ase code File number 097854-1140320	
Official Charge US\$ 416.57	Country Charge US\$ 400,19	Administration Charge US\$ 200.00		

Slovakia Patent number 3137078 Renewal date 01 May 2024 Annuity 10

Invoice item number	<i>Туре</i>	Application number	Proprietor		Cost
0039	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.		US\$ 792.12
Reference		Klipstrick Townsend & Slockton LLP case code		File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860611		097854-1140323	
Official Charge US\$ 296.06	Country Charge US\$ 296.06	Administration Charge US\$ 200.00	y tyty ministrativ to tage allow that your addigation. Canada		

Slovenia Patent number 3137078 Renewal date 01 May 2024 Annuity 10

		•	•		
involce item number 0040	<i>Туре</i> Patent	Application number 15785846.5	Proprietor EIGER BIOPHAR	RMACEUTICALS, INC.	Cost US\$ 640.37
Reference TREATMENT OF H	EPATITIS DELTA VIRUS	Kilpatrick Townsend & Stockt 860612	on LLP case code	File number 097854-1140322	
Official Charge US\$ 163.65	Country Charge US\$ 276.72	Administration Charge US\$ 200.00			

.

.

Ň

.

. .

Part of **Clarivate**

Date	CPA Global account number	Client name	
28 February 2024	2493856	Eiger Biopharmaceuticals, Inc.	

Invoice U483121 continued

invoice item number 0041	<i>туре</i> Patent	Application number 15785846.5	Proprietor EIGER BIOPHARM	ACEUTICALS, INC.	^{Cost} US\$ 1,012.56
Reference TREATMENT OF HI	EPATITIS DELTA VIRUS	Kilpatrick Townsend & Stockton 860615	LLP case code	File number 097854-1140296	
Official Charge US\$ 407.65	Country Charge US\$ 404.91	Administration Charge US\$ 200.00			
Great Britain Pa	atent number 3137078 Re	enewal date 01 May 2024	Annuity 10		
involce item number 0042	Type Patent	Application number 15785846.5	Proprietor EIGER BIOPHARM	ACEUTICALS, INC.	Cost US\$ 675.22
Reference TREATMENT OF HI	EPATITIS DELTA VIRUS	Kilpatrick Townsend & Stockton 860617	1 LLP case code	File number 097854-1140305	
Official Charge US\$ 294.85	Country Charge US\$ 180.37	Administration Charge	den han nör dördöken i nör antikalikeren dörandra och en dör		
Spain Patent nu	mber 15785846.5 Renew	val date 01 May 2024 /	Annuity 10		
Invoice item number 0043	Type Patent	Application number 15785846.5	Proprietor EIGER BIOPHARM	ACEUTICALS, INC.	Cost US\$ 829.15
Reference TREATMENT OF HI	EPATITIS DELTA VIRUS	Kilpatrick Townsend & Stockton 860613	n LLP case code	File number 097854-1140302	
Official Charge US\$ 327,89	Country Charge US\$ 301,26	Administration Charge US\$ 200,00			
Sweden Patent	number 15785846.5 Ren	newal date 01 May 2024	Annuity 10		
Invoice item number 0044	<i>Туре</i> Patent	Application number 15785846.5	Proprietor	ACEUTICALS, INC.	Cost US\$ 830.06
Reference TREATMENT OF H	EPATITIS DELTA VIRUS	Kilpatrick Townsend & Stockto 860614	n LLP case code	File number 097854-1140321	
Official Charge	Country Charge US\$ 203.67	Administration Charge US\$ 200.00			
US\$ 426.39					
	application number 1916200	00.4 Renewal date 01 I	May 2024 Annuity 1	0	
Europe Patent a	application number 1916200 Type Patent	Application number 19162000.4	Proprietor	0 IACEUTICALS, INC.	Cost US\$ 2,980,55
Europe Patent a Invoice item number 0045 Reference	Туре	Application number	Proprietor EIGER BIOPHARN	and a second	
Europe Patent a Invoice item number 0045 Reference TREATMENT OF H Official Charge	Туре Patent	Application number 19162000.4 Kilpatrick Townsend & Stockto	Proprietor EIGER BIOPHARN	IACEUTICALS, INC.	
Involce item number 0045 Reference TREATMENT OF H Official Charge US\$ 2,640.70	Type Patent EPATITIS DELTA VIRUS Country Charge	Application number 19162000.4 Kilpatrick Townsend & Stockto 852526 Administration Charge	Proprietor EIGER BIOPHARN n LLP case code	IACEUTICALS, INC.	
Europe Patent a Invoice item number 0045 Reference TREATMENT OF H Official Charge US\$ 2,640.70	Type Patent EPATITIS DELTA VIRUS Country Charge US\$ 139,85	Application number 19162000.4 Kilpatrick Townsend & Stockto 852526 Administration Charge US\$ 200,00	Proprietor EIGER BIOPHARM n LLP case code 024 Annuity 10 Proprietor	IACEUTICALS, INC.	

Invoice item number	^{Туре}	Application number	Proprietor		US\$ 422
0046	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.		
Reference		Kilpatrick Townsend & Stockton LLP case code		File number	
TREATMENT OF HEPATITIS DELTA VIRUS		860616		097854-1140324	
Official Charge US\$ 185,03	Country Charge US\$ 37.13	Administration Charge US\$ 200.00	na na provinski na sanst di shana shi shkana Mishi da satari		



F6 54577 ISO 9001:2008 CPA Global Limited Registered as a company under the Companies (Jersey) Law 1991, number 93743 Registered Ciffee Untertion House, Castle Street, St Helice, Jersey, JE1 1BL Channel Islands CPA Global Limited previously registered as Computer Patent Annullies Limited

Part of Clarivate

Date	CPA Global account number	Client name
28 February 2024	2493856	Eiger Biopharmaceuticals, Inc.

Invoice U483121 continued

Invoice item number	Туре	Application number	Proprietor		Cost
0047	Patent	201580023585.1	EIGER BIOPHAR	MACEUTICALS, INC.	US\$ 1,237.19
Reference		Klipetrick Townsend & Stockton	LLP case code	File number	
TREATMENT OF H	EPATITIS DELTA VIRUS	732622		097854-1026092	
Official Charge	Country Charge	Administration Charge			
US\$ 767.62	US\$ 269.57	US\$ 200.00			

•

• b

,

Germany Patent number 602015026839.3 Renewal date 01 May 2024 Annuity 10

involce item number	Type	Application number	Proprietor		Cost
0048	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.		US\$ 1,144.33
Reference	Reference		Klipetrick Townsend & Stockton LLP case code File number		
TREATMENT OF HI	TREATMENT OF HEPATITIS DELTA VIRUS		860595 097854-1140299		
Official Cherge US\$ 639.73	Country Charge US\$ 304.60	Administration Charge US\$ 200.00		a na ana amin'ny faritr'ora amin'ny faritr'ora amin'ny faritr'ora amin'ny faritr'ora dia amin'ny faritr'ora ami	

Italy Patent number 502019000037764 Renewal date 01 May 2024 Annuity 10

Involce item number	Туре	Application number	Propriator	Cost
0049	Patent	15785846.5	EIGER BIOPHARMACEUTICALS, INC.	US\$ 856.03
Reference TREATMENT OF HI	EPATITIS DELTA VIRUS	Kilpatrick Townsend & Stockton LL 860600	case code File number 097854-1140310	
Official Charge US\$ 342,18	Country Charge US\$ 313.85	Administration Charge US\$ 200.00	na Yearan yearan katalan a katalan da sakata da sakata ya pada ya katalan ya katalan ya katalan ya sakat ya sa	

U.S.A. Patent number 10828283 Renewal date 10 May 2024 Annuity 01

Involce item number 0050	^{Турө} Small Entity	Application number 16/052386	Proprietor EIGER BIOPHA	RMACEUTICALS, INC.	Cost US\$ 1,000.00
Reference TREATMENT OF H	EPATITIS DELTA VIRUS	Klipatrick Townsond & Stockton 819090	LLP case code	File number 097854-1098916	
Official Charge US\$ 800.00	Country Charge US\$ 0.00	Administration Charge US\$ 200.00	ning Miland Ly Barris, Young Trans. Joint Johnson Hanni	nan pana manana ang kanang	

U.S.A. Patent number 10835496 Renewal date 17 May 2024 Annuity 01

Invoice item number 0051	τγρe Small Entity	Application number 15/567444			Cost US\$ 1,000.00
0051	Small Endly	10/00/444	EIGER BIOPHARMACE	UTICALS, INC.	034 1,000,00
Reference		Klipatrick Townsend & Stockton LL	P case code	File number	
PHARMACEUTICAL	COMPOSITIONS COMPRIS	777350		097854-1064982	
Official Charge	Country Charge	Administration Charpe			
US\$ 800.00	US\$ 0.00	US\$ 200.00			

Europe Patent application number 22744570.7 Renewal date 21 Jun 2024 Annuity 03

Involce item number 0052	Type Patent	Application number 22744570.7	Proprietor EIGER BIOPHAN	RMACEUTICALS, INC.	Cost US\$ 1,366.38
Reference TREATMENT OF CO	ONGENITAL HYPERINSULI	Klipstrick Townsend & Stocktor 1113067	n LLP case code	File number 097854-1416394	
Official Charge US\$ 1,026.53	Country Charge US\$ 139.85	Administration Charge US\$ 200.00	tanan latin ku maku dan upper nersikar pelak lati ku dan ka	n an each a staine (na ga gagadhaine ann an staine staine staine staine staine staine staine staine staine stai	

• •

Part of Clarivate

Date 28 February 2024 Client name Eiger Biopharmaceuticals, Inc. CPA Global account number 2493856

Invoice U483121 continued N

Involce item number	Type	Proprietor		Cos
0053	Small Entity	EIGER BIOPHAR	RMACEUTICALS, INC.	US\$ 562.36
Reference	anda manani si mana ki mini karang kalan angan karang mini karang kanang angan ang	Kilpatrick Townsend & Stockton LLP case code	File number	
	ONGENITAL HYPERINSULI	1113066	097854-1416393	
Official Charge	Country Charge	Administration Charge	A REAL PROPERTY AND A REAL PROPERTY OF THE REAL PRO	
US\$ 127.95	US\$ 234.41	US\$ 200.00		

Irrespective of the Entity size CPA Global pay Canadian patent annuities as Large Entity

٦



Page 11 of 11

This page is intentionally left blank

.

+ + +

Renewal Services Agreement

Patents and Designs Quarterly Automatic Payment Service

Issue Date: August 28, 2017

Eiger Biopharmaceuticals, Inc. 350 Cambridge Avenue Suite 350 Palo Alto, CA 94306

CPA Global Limited Company Number 93743 Liberation House Castle Street Jersey JE1 1BL

Eiger Biopharmaceuticals, Inc.

Version 2.1

Channel Islands

Kilpatrick Townsend & Stockton LLP Lest Revised February 2017

)

Outsourced – Full Patent Quarterly Automatic Page 1 of 9 ١

TABLE OF CONTENTS

OPERA	TING PROCEDURES	3
1.	SERVICE DESCRIPTION	3
2.	DATA EXCHANGE	3
3.	ON-GOING COMMUNICATION AND DATA MANAGEMENT	3
4.	SERVICE CHARGE	4
5.	CREDIT PERIOD	4
6.	CURRENCY FOR INVOICE AND PAYMENT	4
7.	CPA START PAY DATE	4
8.	WORKFLOW DIAGRAM	5
9.	KEY DATES	6
TERMS	S AND CONDITIONS OF SUPPLY OF CPA GLOBAL LIMITED	7
1.	APPLICATION	7
2.	FORMATION OF CONTRACT	7
3.	INSTRUCTIONS	7
4.	AGENTS AND OTHER SUB-CONTRACTORS	7
5.	CHARGES	7
6.	PAYMENT	8
7.	CONFIDENTIALITY	
8.	RECORDS	8
9.	TERMINATION	8
10.	FORCE MAJEURE	8
11.	ASSIGNMENT	9
12.	GOVERNING LAW	
13.	NOTICE AND COMMUNICATIONS	9

Eiger Biopharmaceuticais, Inc.

Version 2.1

Kilpatrick Townsend & Stockton LLP Last Revised February 2017 Outsourced – Full Patent Quarterly Automatic Page 2 of 9

· -

٦

T

.

OPERATING PROCEDURES

1. SERVICE DESCRIPTION

- 1.1 We will handle the payment of your patent and design renewal fees.
- 1.2 We will send you a consolidated quarterly renewal notice approximately three months in advance of the beginning of the renewal due period as set out in the table under the heading "Key Dates". The renewal notice will be sent by paper and/or via electronic file.
- 1.3 You will inform us of cases that should be abandoned by the last date for abandonment as set out in the table under the heading "Key Dates". Abandon instructions may be sent to us either using CPA Direct, our online service, via electronic batch transfer or via fax or mail. We will confirm an abandon instruction by sending a remove acknowledgement report. If we have not received an abandon instruction we will instruct payment of the renewal fee.
- 1.4 We will send you a quarterly involce. The involce will be sent approximately one month prior to the beginning of the renewal quarter. The involce will be sent on paper and via electronic file (if required).
- 1.5 If an abandon instruction is received after the relevant invoice has been issued, we will issue a credit only if we have not already actioned the renewal.
- 1.6 We will store all official receipts for you. A copy may be requested at any time.

2. DATA EXCHANGE

- 2.1 Your patent firm will provide us with an initial data set for all granted and pending cases.
- 2.2 We will analyse the data to determine data quality and send your patent firm any queries, where we identify difficulties. You will be responsible for diligently working with your patent firm to resolve all data discrepancies in a timely manner. Your patent firm will communicate the resolution of these discrepancies to us.
- 2.3 Once the discrepancies are resolved, we will load the data onto the live system and provide your patent firm with a portfolio file of all cases loaded. They will review this portfolio file and approve the contents.

3 ON-GOING COMMUNICATION AND DATA MANAGEMENT

- 3.1 On a regular basis, your patent firm will send us data for new cases as well as updates to existing case data in a mutually agreed format.
- 3.2 We will update data transferred by your patent firm to us and provide your patent firm with details of the changes on paper or via standard electronic files.

Eiger Biopharmaceuticals, Inc.	Kilpatrick Townsend & Stockton	Outsourced – Fuli Patent Quarterly Automatic
	LLP	Patent Quarterly Automatic
Version 2.1	Last Revised February 2017	Page 3 of 9

- 3.3 Your patent firm will update their records in accordance with our instructions from time to time.
- 3.4 We will update your data on our system based on data received from third parties and send your patent firm paper input reports. Your patent firm will check the contents of the reports and update your data accordingly.
- 3.5 In the event your patent firm ceases to be responsible for any obligations under this clause 3, it shall be incumbent on you to notify us and fulfil their obligations yourself in the interim until we mutually agree on how data reporting will be handled in the future.

4. SERVICE CHARGE

4.1 We will charge you USD 200 for each renewal (the "Service Charge"). We will give you not less than 6 months' notice of any increase in our Service Charge. Additional charges are described in Section 5 of the Terms and Conditions of Supply attached hereto.

5. CREDIT PERIOD

5.1 Your credit period is 30 days from the date that our invoice is issued.

6. CURRENCY FOR INVOICE AND PAYMENT

6.1 The currency for invoice and payment will be US Dollars.

7. CPA START PAY DATE

7.1 We will begin making payments pursuant to the terms of this agreement beginning with renewals due on or after October 1, 2017, provided you have signed and returned this agreement to us within 30 days of the issue date we have specified on the first page of this agreement. If you fail to return a signed agreement to us by such date, we reserve the right to delay the date in which we initiate your automatic service under the terms of this Agreement. There will be no interruption in your service during the transition from your current instruct account to your automatic account.

Eiger Blopharmaceuticals, Inc.

Version 2.1

Kilpatrick Townsend & Stockton LLP Last Revised February 2017 Outsourced – Full Patent Quarterly Automatic Page 4 of 9

,

.

8. WORKFLOW DIAGRAM

CPA monitors your cases ۷ CPA sends one quarterly re-newal notice to you Ŧ If no abandon Instructions You send abandon instruc-tions to CPA by the deadline date have been received by the deadline then CPA renews the cases with the agent or PTO ¥ ۳ CPA sends a remove ac-CPA sends one quarterly in-voice to you knowledgment report to you for all abandoned cases ▼ ▼ CPA stores patent official CPA no longer monitors your abandoned cases receipts – or sends them to you – per your renewal ser-vices agreement

Elger Biopharmaceuticals, Inc.

Version 2.1

Klipatrick Townsend & Stockton LLP Last Revised February 2017

Outsourced – Full Patent Quarterly Automatic Page 5 of 9

١

9. KEY DATES

1

Patent and design renewals due		Renewal notice date ¹	Last date for abandonment ²	CPA invoice date	
	January				
Quarter 1	February March	September	20 November	28 November	
Quarter 2	April May June	December	20 February	28 February	
Quarter 3	July August September	March	20 May	28 May	
Quarter 4	October November December	June	20 August	28 August	

1. We will send you only one renewal notice approximately 3 months prior to the due period.

This is the last date on which we can accept your abandon instruction. If abandon instructions are received after this date we may not be able to refund any cost of renewal.

Elger Biopharmaceuticals, Inc.

Version 2.1

Klipatrick Townsend & Stockton LLP Last Revised February 2017 Outsourced – Full Patent Quarterly Automatic Page 6 of 9

TERMS AND CONDITIONS OF SUPPLY OF CPA GLOBAL LIMITED

3.4

4.

4.1

5.

5.1

5.2

5.4

5.5

APPLICATION 1.

- 1.1 These conditions shall govern and be incorporated into every contract made by CPA Global Limited ("us", "we" and cognate terms) or on our behalf with clients ("you") for the provision of intellectual property related professional services ("Services") and shall subject to condition 1.2 below prevail over any terms or conditions contained or referred to in any documents submitted by you or previously submitted by us or in correspondence or elsewhere.
- The details of the Services that we shall provide 1.2 to you are set out in our operating procedures (the "Operating Procedures"). We may change the Services and/or Operating Procedures at any time upon written notice to you.
- 1.3 A variation of these conditions is valid only if it is In writing and signed by or on behalf of us.
- No failure to enforce or delay in enforcing any of 1.4 these conditions shall operate as a waiver of any of them and no partial or single exercise shall prevent any other or future exercise of that or any other right.

FORMATION OF CONTRACT 2.

- 2.1 A contract shall arise between us on whichever is the earlier of our actual receipt of your instructions to act or a renewal notice issued by us and our acting upon your instructions.
- Our acceptance of any oral instructions from you 2.2 shall be effective only when such instructions 5.3 have been confirmed in writing by letter or facsimile transmission. Electronic instructions will be accepted only if by the CPA Direct System to which separate conditions apply, or by an electronic interface approved by us.

З. INSTRUCTIONS

- 3.1 A condition to our acting on your behalf will be that you respond promptly, clearly and completely to any request we may make for instructions, information, technical data, documents and payment of charges.
- Without prejudice to the need for you to respond 3.2 promptly, if we need your response by a specific deadline we will endeavour to say so when seeking instructions. If you miss a deadline or send us insufficiently clear or timely or incomplete instructions we shall have no liability for any loss which may arise and we shall not be under any obligation to take any steps to preserve or to protect your rights further. Nevertheless, if at our sole discretion we take any such steps, then you shall pay us for all charges, cost of work done, overheads and disbursements incurred, each of which may include premia and/or special charges to reflect urgency and disruption.
- 3.3 You agree that we may rely and act upon instructions from your authorised agent whose

Elger Blopharmaceuticals, Inc

Version 2.1

details you have supplied to us until we receive your written signed instructions to the contrary.

Subject to these conditions we will proceed on the basis that our duty to you is to do what we consider is necessary properly to protect and preserve your rights.

AGENTS AND OTHER SUB-CONTRACTORS

In order to provide the Services we may need to instruct local agents practising in the jurisdiction of each relevant registry or other independent specialist providers. The naming of any third party referral firm(s) in our correspondence is not intended to give rise to any agency relationship. Each party is intended to be a principal in its own right and the contract for the Services is between you and us only, in accordance with these conditions.

CHARGES

- You shall pay the Service Charge for the Services as set out in Clause 4 of the Operating Procedures.
- You shall also pay our charges comprising our estimate of our charges in respect of submission to the relevant registries in each jurisdiction ("Official Charge") and which vary from time to time and, where applicable a "Country Charge" which is set out in a tariff (which may vary from time to time), a current copy of which is available on request.
- Any sums of money that may at any time require to be converted from one currency into the currency in which we have agreed to invoice you will be so converted at our rates from time to time and be subject to a charge for managing such funds.
- All charges are subject to variation in the light of changes to underlying charges and/or for correction of errors. In addition, we shall be entitled to increase our charges once each year by no more than the greater of 5% or the U.S. Consumer Price Index.
- On each occasion upon which we send you a renewal notice in relation to the renewal of a particular intellectual property right we give you our best estimate of the likely total aggregate charges likely to be payable in respect thereof (including the Service Charge, the Country Charge and the Official Charge) on the basis that the transaction proceeds in an expected and standard manner. Your instruction to us to proceed (whether express or, if otherwise so agreed, by failure to instruct us not to proceed) shall constitute your acceptance of, and agreement to pay such fee and, if applicable, to pay later after they have arisen and been invoiced any supplements thereto that may arise or become appropriate in the light of any unexpected work, change of circumstances or further expenses becoming necessary. We shall submit to you an involce for the amount of such Kilpatrick Townsend & Stockton

Outsourced - Full Patent Quarterly Automatic Page 7 of 9 Last Revised February 2017

estimate after your instruction or deemed instruction to us to proceed.

- 5.6 VAT and any other relevant tax or duty payable, if any, by you on our supply of Services shall be added to all fees.
- 5.7 You acknowledge that it is our policy not to pay accumulated annulties or back fees arising in certain countries at the time of grant or acceptance of an application, and it is your responsibility to arrange payment of such fees directly with your associate.
- 6. PAYMENT
- 6.1 Unless otherwise agreed, payment of involces shall be made in full within 30 days from the date that our involce is issued. Time shall be of the essence of payment. Interest will be charged on any amounts overdue at the rate of 1% per month or part thereof. We may suspend the supply of Services to you where any amounts are overdue under any contract until all such amounts have been paid.
- 6.2 If in our opinion your creditworthiness deteriorates before completion of performance of our Services we may require full or partial payment of all or any fees prior to performance or the provision of security by you in a form acceptable to us.
- 6.3 We shall be entitled to offset any amount owing to us from you against any amount owed to you by us.
- 7. CONFIDENTIALITY
- Each of you and we undertake to the other that it 7.1 will not during the term of this agreement or at any time thereafter use, divulge or communicate to any person, except its professional representatives or advisers or as may be required by law or any legal or regulatory authority or pursuant to performance of its obligations under a contract made pursuant hereto, any confidential information relating to the other's business, financial or other affairs which is not in the public domain concerning the other party which may have, or may in future, come to its knowledge under the provisions hereof and each of you and we shall use reasonable endeavours to prevent the publication or disclosure of any such information. This provision shall not apply to information already known to the receiving party prior to its receipt hereunder or which subsequently comes into the public domain or its knowledge other than as a result of a breach hereof.

8. RECORDS

8.1 We will maintain records in connection with all matters in respect of which we provide the Services to you. Any file which we may open in connection with the Services shall be and shall remain our property at all times. When we have completed the contract for the Services in respect of any matter we may destroy any related file at any time after the expiry of one year.

Eiger Blopharmaceuticals, Inc

Version 2.1

Klipatrick Townsend & Stockton LLP Last Revised February 2017

10.3

If you wish to have access to any of our files after we have ceased to act for you then, provided that such file has not already been destroyed pursuant to condition 8.1 above, we shall be entitled to require you to make payment of any monies then still due from you to us and in addition to charge you a reasonable fee for the work involved in giving you such access.

TERMINATION

8.Z

9,

9.1

9.2

9.4

10.

10.1

- Unless otherwise agreed, either you or we may terminate our provision of the Services by giving to the other not less than one year's notice in writing expiring at any time.
- On or at any time after the occurrence of any of the events in condition 9.3, we may suspend further performance of Services for you and/or terminate any contract with you with immediate effect by written notice to you.
- 9.3 The events are:
 - (a) you being in breach of an obligation under a contract with us;
 - (b) you passing a resolution for your winding up or a court of competent jurisdiction making an order for your winding up or dissolution;
 - (c) your entering administration, the making of an administration order in relation to you or the appointment of a receiver over, or an encumbrancer taking possession of or selling, any of your assets;
 - (d) your making an arrangement or composition with your creditors generally or applying to a court of competent jurisdiction for protection from your creditors.
 - Upon any termination, any of your indebtedness to us shall become immediately due and payable and we shall be under no further obligation to provide any Services to you.

FORCE MAJEURE

- Where a Force Majeure Event takes place we shall use our reasonable endeavours to carry out the Services.
- 10.2 Notwithstanding 10.1 above, if we are prevented, hindered or delayed from or in supplying any Services in accordance with these conditions by a Force Majeure Event we shall notify you as soon as reasonably possible and we may, at our option:
 - (a) suspend performance while the Force Majeure Event continues;
 - (b) apportion available resources between our clients as we decide;
 - (c) terminate any contract so affected with Immediate effect by written notice to you;
 - and we shall not be liable for any loss or damage suffered by you as a result.
 - In this condition "Force Majeure Event" means an event or circumstance beyond our reasonable control including, without limitation, strikes,

Outsourced – Full Patent Quarterly Automatic Page 8 of 9

۰.,

lockouts and other industrial disputes relating to our workforce.

ASSEGRMENT t١

You may not assagn or transfer, or purport to assagn or transfer, any of your rights or abligations under a contract without our prior written consent. We may assign, transfer and/or subcontract the whole or any part of this contract without notice to you.

GOVERNING LAW 12

These conditions and any contract made under them shall be poverned by and construct in accordance with Virginia law and the courts of Virginia shall have exclusive jurisdoction

13 NOTICE AND COMMUNICATIONS

Any notice, demand or other communication given or made under or in connection with the matters

We agree to the above.

Signed for and on behalf of Elger Siopharmaceuticals, Inc.

Matthew-Bys-cod Krvin Kastor, 350 Cambridge Avenue, Suite 350, Polo Alto, CA 94306

Signature: Renni Rester Name: Kevin KastER POSIDON: VP, INTELLECTUAL ROPERTY Date: 31 August 2017

Signed for and on behalf of CPA Global Limited Liberation House, Castle Street, Jersey, JE1 18L, Channel Islands.

11.

21 Signatures Amanda Harris

Name:

Authorised Signatory Position: _ - 4 SEP 2017

Date:

Liver Diopharmaceuticals, Inc. Vendon 2.1

Képstrick Townsend & Stockton Last Revised February 2017

Outpoursed - Full Patent Quarterly Automatic Pace 9 of 9

have been duly given or made as follows: (a) if personally delivered, upon delivery at the address of the relevant party; (b) If sent by an mail, 5 days after the date of posting; and (c) # sent by fax, when despetched;

contemplated by these conditions shall be in writing and shall be delivered personally or sere by fail or prepeted air mail (to in our case our registerred office from time to time marked for the attention of (the Secretary) and shall be deemed to

provided that if, in accordance with the above provided, any such hotos, demand or other computation would otherwise be deemed to be given or made after 5.00 p m, such hotos, demand or other communication shall be deemed to be given or make at 9.00 a.m. on the next usual business day in the place of receipt.